HBM (HKG:2142) plans to repurchase up to HK$200 million of shares under a buyback mandate, according to a Thursday filing with the Hong Kong bourse.
The drug company has so far allocated HK$240 million for share buybacks in 2025 on a year-to-date basis, the filing said.
Shares surged 12% during Friday's afternoon trading.